Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

A Study to Investigate the Efficacy of an Experimental Dentifrice Containing Stannous Fluoride in Improving Gingival Health

maanantai 10. elokuuta 2026 päivittänyt: HALEON

An 8-Week Randomized, Controlled, Examiner-Blind, Clinical Study Investigating the Efficacy of an Experimental Dentifrice Containing Stannous Fluoride in Improving Gingival Health

The aim of this study will be to evaluate the ability of using an experimental dentifrice containing 0.454 percent (%) weight for weight (w/w) Stannous Fluoride (SnF2) to reduce gingivitis and plaque accumulation, compared with a regular fluoride toothpaste (negative control) in participants with mild to moderate gingivitis.

Tutkimuksen yleiskatsaus

Yksityiskohtainen kuvaus

This will be a single-center, 8-week randomized, controlled, single blind (examiner only), 2-treatment arm, parallel group, stratified study, to evaluate the efficacy of using an experimental dentifrice containing 0.454% w/w Stannous Fluoride, twice daily in reducing gingivitis and plaque accumulation in a population with a clinically measurable level of gingivitis. The clinical efficacy of the experimental dentifrice will be compared to a commercially available regular fluoride dentifrice as negative control. Sufficient participants will be screened to randomize approximately 110 participants (approximately 55 per group) to ensure approximately 100 evaluable participants (approximately 50 per group) complete the study.

Opintotyyppi

Interventio

Ilmoittautuminen (Arvioitu)

110

Vaihe

  • Ei sovellettavissa

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskeluyhteys

Opiskelupaikat

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

  • Aikuinen
  • Vanhempi Aikuinen

Hyväksyy terveitä vapaaehtoisia

Joo

Kuvaus

Inclusion Criteria:

  • Participant provision of a signed and dated informed consent document indicating that the participant will have been informed of all pertinent aspects of the study before any assessment is performed.
  • A participant who is willing and able to comply with scheduled visits, treatment plan and other study procedures, study restrictions, Lifestyle considerations.
  • A participant in good general and mental health with, in the opinion of the investigator or medically qualified designee, no clinically significant or relevant abnormalities in medical history or upon oral examination, or condition, that would impact the participant's safety, wellbeing or the outcome of the study, if they were to participate in the study, or affect the participant's ability to understand and follow study procedures and requirements.

Exclusion Criteria:

  • A participant who is an employee of the investigational site, either directly involved in the conduct of the study or a member of their immediate family; or an employee of the investigational site otherwise supervised by the investigator; or a Haleon employee directly involved in the conduct of the study or a member of their immediate family.
  • A participant who has participated in other studies (including non-medicinal studies) involving investigational product(s) within 30 days prior to study entry and/or during study participation.
  • A participant with, in the opinion of the investigator or medically qualified designee, an acute or chronic medical, psychiatric condition or laboratory abnormality or any other clinical serious or unstable conditions (Example(e.g.), cardiovascular diseases, diabetes, liver disorders, and kidney disorders) that may increase the risk associated with study participation or investigational product administration, or may interfere with the interpretation of study results and, in the judgment of the investigator or medically qualified designee, would make the participant inappropriate for entry into this study.
  • A participant who is a pregnant female (self-reported) or intending to become pregnant over the duration of the study.
  • A female participant who is breastfeeding.
  • A participant with known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients.
  • A participant unwilling or unable to comply with the lifestyle considerations described in this protocol.
  • A participant who is a current smoker or an ex-smoker (including vaping) who stopped within 6 months of Screening.
  • A participant who is using smokeless forms of tobacco (example, chewing tobacco, gutkha, paan containing tobacco, nicotine-based e-cigarettes).
  • A participant who has diagnosed xerostomia or is taking any medication that in the view of the investigator, is causing xerostomia.
  • A participant who has a medical condition which could directly influenced gingival bleeding (e.g., type 2 diabetes).
  • A participant who has a bleeding disorder that could affected study outcomes and/or participant safety.
  • A participant who has a recent history (within the last year) of alcohol or other substance abuse.
  • A participant who has a severe oral condition (e.g., acute necrotizing ulcerative gingivitis or oral or peri-oral ulceration including herpetic lesions) that could, in the opinion of the investigator, compromise study outcomes or the oral health of the participant/examiner if they participate in the study.
  • Presence of a tongue or lip piercing, or any other oral feature that could interfere with the usage of a toothbrush.
  • A participant currently taking any such medication or oral care product which in opinion of the investigator could affect gingival condition.
  • Dental exclusions:

    1. A participant who has active caries that could, in the opinion of the investigator, compromise study outcomes or the oral health of the participant if they participate in the study.
    2. A participant who has dentures (partial or full).
    3. A participant who has fixed orthodontic appliances or is undergoing active or recent (within 3 months of Screening) orthodontic treatment, which, in the opinion of the investigator, could interfere with study procedures, assessments or outcomes.
    4. A participant who has other orthodontic devices (e.g., bands, fixed retainers, or removable retainers) that could, in the opinion of the investigator, interferes with study procedures, assessment, or outcomes.
    5. A participant who has numerous restorations in a poor state of repair.
    6. A participant who has any dental condition (e.g., overcrowding) that could, in the opinion of the investigator, compromise study outcomes or the oral health of the participant if they participate in the study.
    7. A participant who has had dental prophylaxis and teeth bleaching within 12 weeks of Screening.
    8. A participant who has high levels of extrinsic stain or calculus deposits, in the opinion of the investigator, that could interfered with plaque assessments.
  • A participant who has previously been enrolled in this study.
  • A participant who, in the opinion of the investigator or medically qualified designee, should not participate in the study.

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Hoito
  • Jako: Satunnaistettu
  • Inventiomalli: Rinnakkaistehtävä
  • Naamiointi: Yksittäinen

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: Test Dentifrice
Participants will brush their teeth thoroughly for at least one timed minute twice daily (morning and evening) for 8 Weeks, using a full ribbon of Test Dentifrice on the head of the toothbrush provided.
Kokeellinen hammastahna, joka sisältää 0,454 % p/p SnF2.
Active Comparator: Reference Dentifrice
Participants will brush their teeth thoroughly for at least one timed minute twice daily (morning and evening) for 8 Weeks, using a full ribbon of Reference Dentifrice on the head of the toothbrush provided.
A marketed regular fluoride dentifrice.

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Change from Baseline in Overall Modified Gingival Index (MGI) at Week 8
Aikaikkuna: Baseline and Week 8
The MGI assessment is a non-invasive visual evaluation to assess the symptoms of gingivitis. It will be assessed on all scorable teeth. For each tooth, 3 scores will be recorded and will be scored on a 5-point scale ranging from 0 to 4, where 0 equals (=) Absence of inflammation, 1= Mild inflammation; slight or little change in color; little change in texture of any portion of the marginal/ papillary gingival unit, 2= Mild inflammation; criteria as above, but involving the entire marginal/ papillary gingival unit, 3= Moderate inflammation; glazing, redness, edema, and/ or hypertrophy of the marginal/ papillary gingival unit, 4= Severe inflammation; marked redness, edema and/ or hypertrophy of the marginal/ papillary gingival unit, spontaneous bleeding, congestion, or ulceration. Change from Baseline= Week 8 score minus Baseline score. Lower scores indicate symptom improvement.
Baseline and Week 8

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Change from Baseline in Interproximal MGI at Week 8
Aikaikkuna: Baseline and Week 8
The MGI assessment is a non-invasive visual evaluation to assess the symptoms of gingivitis. It will be assessed on all scorable teeth. For each tooth, 3 scores will be recorded and will be scored on a 5-point scale ranging from 0 to 4, where 0= Absence of inflammation, 1= Mild inflammation; slight or little change in color; little change in texture of any portion of the marginal/ papillary gingival unit, 2= Mild inflammation; criteria as above, but involving the entire marginal/ papillary gingival unit, 3= Moderate inflammation; glazing, redness, edema, and/ or hypertrophy of the marginal/ papillary gingival unit, 4= Severe inflammation; marked redness, edema and/ or hypertrophy of the marginal/ papillary gingival unit, spontaneous bleeding, congestion, or ulceration. Change from Baseline= Week 8 score minus Baseline score. Lower scores will indicate symptom improvement.
Baseline and Week 8
Change from Baseline in Overall Turesky Modification of the Quigley Hein Plaque Index (TPI) at Week 8
Aikaikkuna: Baseline and Week 8
TPI will be used to assess plaque on all gradable teeth. The plaque will first be disclosed using a plaque disclosing dye solution. The TPI will be assessed on the facial and lingual surfaces of each scorable tooth. Three scores will be recorded buccally/labially and three scores lingually/palatally. The disclosed plaques will be scored using a 6-point scale ranging from 0 to 5, where 0= No plaque, 1= Separate flecks of plaque at the cervical margin, 2= Thin continuous band of plaque (up to 1 millimeter[mm]) at the cervical margin, 3= Band of plaque wider than 1 mm but covering less than (<) 1/3 of the tooth surface, 4= Plaque covering greater than or equal to (≥) 1/3 but < 2/3 of the tooth surface, 5= Plaque covering ≥ 2/3 of the tooth surface. Change from Baseline= Week 8 score minus Baseline score. Lower scores will indicate symptom improvement.
Baseline and Week 8
Change from Baseline in Interproximal TPI at Week 8
Aikaikkuna: Baseline and Week 8
TPI will be used to assess plaque on all gradable teeth. The plaque will first be disclosed using a plaque disclosing dye solution. The TPI will be assessed on the facial and lingual surfaces of each scorable tooth. Three scores will be recorded buccally/labially and three scores lingually/palatally. The disclosed plaques will be scored using a 6-point scale ranging from 0 to 5, where 0= No plaque, 1= Separate flecks of plaque at the cervical margin, 2= Thin continuous band of plaque (up to 1 mm) at the cervical margin, 3= Band of plaque wider than 1 mm but covering < 1/3 of the tooth surface, 4= Plaque covering ≥ 1/3 but < 2/3 of the tooth surface, 5= Plaque covering ≥ 2/3 of the tooth surface. Change from Baseline= Week 8 score minus Baseline score. Lower scores will indicate symptom improvement.
Baseline and Week 8

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Sponsori

Tutkijat

  • Päätutkija: Jeffery L Milleman, DDS, Salus Research Inc

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Maanantai 13. heinäkuuta 2026

Ensisijainen valmistuminen (Arvioitu)

Torstai 1. lokakuuta 2026

Opintojen valmistuminen (Arvioitu)

Torstai 1. lokakuuta 2026

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Perjantai 10. heinäkuuta 2026

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Perjantai 10. heinäkuuta 2026

Ensimmäinen Lähetetty (Todellinen)

Keskiviikko 15. heinäkuuta 2026

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Keskiviikko 12. elokuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Maanantai 10. elokuuta 2026

Viimeksi vahvistettu

Lauantai 1. elokuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

JOO

IPD-suunnitelman kuvaus

Anonymized individual participant data and study documents can be requested for further research from ww.clinical-trial-register@haleon.com.

IPD-jaon aikakehys

IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

IPD-jaon käyttöoikeuskriteerit

Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension can be granted, when justified, for up to another 12 months

IPD-jakamista tukeva tietotyyppi

  • STUDY_PROTOCOL
  • MAHLA
  • ICF

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa